ReviewWorld journal of gastroenterology2014
Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- An Update on the Potential Roles of E2F Family Members in Colorectal Cancer.Cancer management and research · 2021Review
- Identification and Validation of a Six Immune-Related Genes Signature for Predicting Prognosis in Patients With Stage II Colorectal Cancer.Frontiers in genetics · 2021Article
- Five-year follow-up study of stage I-IV rectal cancer including EGFR immunoexpression and p21 immunoactivity.Przeglad gastroenterologiczny · 2021Article
- Circ-MFN2 Positively Regulates the Proliferation, Metastasis, and Radioresistance of Colorectal Cancer by Regulating the miR-574-3p/IGF1R Signaling Axis.Frontiers in genetics · 2021Article
- Article
- The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma.Oncotarget · 2020Article
- P21 is not a prognostic marker for rectal cancer - five-year follow up study of rectal cancer in stages I-IV.Contemporary oncology (Poznan, Poland) · 2020Article
- Biochemical Markers of Colorectal Cancer - Present and Future.Cancer management and research · 2020Review
- Apoptotic Effects of Drug Targeting Conjugates Containing Different GnRH Analogs on Colon Carcinoma Cells.International journal of molecular sciences · 2019Article
- Conversion to resectability using transcatheter arterial chemoembolization alternating with mFOLFOX6 in patients with colorectal liver metastases.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2019Article
- Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6.Oncotarget · 2017Article
- Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.Expert opinion on therapeutic targets · 2016Review
- Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells.Biomedicines · 2016Review
- Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells.Immune network · 2016Review
- Pharmacologic resistance in colorectal cancer: a review.Therapeutic advances in medical oncology · 2016Review
- May CTC technologies promote better cancer management?The EPMA journal · 2015Article
- Potentiating effects of GHRH analogs on the response to chemotherapy.Cell cycle (Georgetown, Tex.) · 2015Article
- New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor.Oncotarget · 2015Article
- Senescence of tumor cells induced by oxaliplatin increases the efficiency of a lipid A immunotherapy via the recruitment of neutrophils.Oncotarget · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of new cytotoxic substances as well as agents that target vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling has improved clinical outcome of patients with metastatic colorectal cancer (mCRC). In this review we summarize the most relevant clinical data on VEGF and EGFR targeting regimens in mCRC. The effects of available treatment strategies for mCRC are often temporary, with resistance and disease progression developing in most patients. Thus, new treatment strategies are urgently needed. Some GI peptides including gastrin and gastrin releasing peptide, certain growth factors such as insulin-like growth factor-I and II and neuropeptides such as growth hormone releasing hormone (GHRH) are implicated in the growth of CRC. Experimental investigations in CRC with antagonistic analogs of bombesin/gastrin-releasing peptide, GHRH, and with cytotoxic peptides that can be targeted to peptide receptors on tumors, are summarized in the second part of the review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.